[1] Chughtai T, Parchani A, Strandvik G, Verma V, Arumugam S, El-Menyar A, Rizoli S, Al-Thani H. Trauma intensive care unit (TICU) at Hamad General Hospital. Qatar Med J. 2020 Feb 6;2019(2):5.
[2] Khalifa Andrew,Avraham Jacob B,Kramer Kristina Z et al. Surviving traumatic cardiac arrest: Identification of factors associated with survival.[J] .Am J Emerg Med, 2021, 43: 83-87.
[3] Pantoja Pachajoa Diana A,Palacios Huatuco René M,Bruera Nicolás et al. Minimally invasive splenectomy in grade IV splenic trauma: A case report associated with high-grade renal trauma.[J] .Int J Surg Case Rep, 2021, 79: 28-33.
[4] Fu Chih-Yuan,Bajani Francesco,Bokhari Marissa et al. Age itself or age-associated comorbidities? A nationwide analysis of outcomes of geriatric trauma.[J] .Eur J Trauma Emerg Surg, 2021, doi:10.1007/s00068-020-01595-8
[5] Mustafić S, Brkić S, Prnjavorac B, Sinanović A, Porobić Jahić H, Salkić S. Diagnostic and prognostic value of procalcitonin in patients with sepsis. Med Glas (Zenica). 2018. 15(2): 93-100.
[6] Yu H, Nie L, Liu A, et al. Combining procalcitonin with the qSOFA and sepsis mortality prediction. Medicine (Baltimore). 2019. 98(23): e15981.
[7] Liu T, Liu J, Tian C, Wang H, Wen M, Yan M. LncRNA THRIL is upregulated in sepsis and sponges miR-19a to upregulate TNF-α in human bronchial epithelial cells. J Inflamm (Lond). 2020. 17: 31.
[8] De Oro N, Gauthreaux ME, Lamoureux J, Scott J. The Use of Procalcitonin as a Sepsis Marker in a Community Hospital. J Appl Lab Med. 2019. 3(4): 545-552.
[9] Sakyi SA, Enimil A, Adu DK, et al. Individual and combined bioscore model of presepsin, procalcitonin, and high sensitive C - reactive protein as biomarkers for early diagnosis of paediatric sepsis. Heliyon. 2020. 6(9): e04841.
[10] Naderpour Z, Momeni M, Vahidi E, Safavi J, Saeedi M. Procalcitonin and D-dimer for Predicting 28-Day-Mortality Rate and Sepsis Severity based on SOFA Score; A Cross-sectional Study. Bull Emerg Trauma. 2019. 7(4): 361-365.
[11] Downes KJ, Fitzgerald JC, Weiss SL. Utility of Procalcitonin as a Biomarker for Sepsis in Children. J Clin Microbiol. 2020. 58(7).
[12] Gregoriano C, Heilmann E, Molitor A, Schuetz P. Role of procalcitonin use in the management of sepsis. J Thorac Dis. 2020. 12(Suppl 1): S5-S15.
[13] Song J, Park DW, Moon S, et al. Diagnostic and prognostic value of interleukin-6, pentraxin 3, and procalcitonin levels among sepsis and septic shock patients: a prospective controlled study according to the Sepsis-3 definitions. BMC Infect Dis. 2019. 19(1): 968.
[14] Hosomi S, Yamagami H, Itani S, et al. Sepsis Markers Soluble IL-2 Receptor and Soluble CD14 Subtype as Potential Biomarkers for Complete Mucosal Healing in Patients With Inflammatory Bowel Disease. J Crohns Colitis. 2018. 12(1): 87-95.
[15] Nguyen T, Nguyen HT, Wang PC, Chen SC. Identification and expression analysis of two pro-inflammatory cytokines, TNF-α and IL-8, in cobia (Rachycentron canadum L.) in response to Streptococcus dysgalactiae infection. Fish Shellfish Immunol. 2017. 67: 159-171.
[16] Das CR, Tiwari D, Dongre A, et al. Deregulated TNF-Alpha Levels Along with HPV Genotype 16 Infection Are Associated with Pathogenesis of Cervical Neoplasia in Northeast Indian Patients. Viral Immunol. 2018. 31(4): 282-291.
[17] Popescu M, Cabrera-Martinez B, Winslow GM. TNF-α Contributes to Lymphoid Tissue Disorganization and Germinal Center B Cell Suppression during Intracellular Bacterial Infection. J Immunol. 2019. 203(9): 2415-2424.
[18] Schmidt de Oliveira-Netto AC, Morello LG, Dalla-Costa LM, et al. Procalcitonin, C-Reactive Protein, Albumin, and Blood Cultures as Early Markers of Sepsis Diagnosis or Predictors of Outcome: A Prospective Analysis. Clin Pathol. 2019. 12: 2632010X19847673.
[19] Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016. 315(8): 801-10.
[20] Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. Lancet. 2018. 392(10141): 75-87.
[21] Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017. 45(3): 486-552.
[22] Coopersmith CM, De Backer D, Deutschman CS, et al. Surviving sepsis campaign: research priorities for sepsis and septic shock. Intensive Care Med. 2018. 44(9): 1400-1426.
[23] Bracht H, Hafner S, Weiß M. [Sepsis Update: Definition and Epidemiology]. Anasthesiol Intensivmed Notfallmed Schmerzther. 2019. 54(1): 10-20.
[24] Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med. 2017. 376(23): 2235-2244.
[25] Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive Care Med. 2018. 44(6): 925-928.
[26] Moss SR, Prescott HC. Current Controversies in Sepsis Management. Semin Respir Crit Care Med. 2019. 40(5): 594-603.
[27] Singer M. Antibiotics for Sepsis: Does Each Hour Really Count, or Is It Incestuous Amplification. Am J Respir Crit Care Med. 2017. 196(7): 800-802.
[28] Chen AX, Simpson SQ, Pallin DJ. Sepsis Guidelines. N Engl J Med. 2019. 380(14): 1369-1371.
[29] Spiegel R, Farkas JD, Rola P, et al. The 2018 Surviving Sepsis Campaign's Treatment Bundle: When Guidelines Outpace the Evidence Supporting Their Use. Ann Emerg Med. 2019. 73(4): 356-358.
[30] Napolitano LM. Sepsis 2018: Definitions and Guideline Changes. Surg Infect (Larchmt). 2018. 19(2): 117-125.
[31] Palmer J, Pandit V, Zeeshan M, et al. The acute inflammatory response after trauma is heightened by frailty: A prospective evaluation of inflammatory and endocrine system alterations in frailty. J Trauma Acute Care Surg. 2019. 87(1): 54-60.
[32] Georgescu AM, Banescu C, Azamfirei R, et al. Evaluation of TNF-α genetic polymorphisms as predictors for sepsis susceptibility and progression. BMC Infect Dis. 2020. 20(1): 221.
[33] Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013. 13(5): 426-435.